How big is scPharmaceuticals, Inc.?

As of Jun 18, scPharmaceuticals, Inc. has a market capitalization of 210.64 million and reported net sales of 41.98 million, with a net profit loss of 90.77 million over the latest four quarters. The company has shareholder's funds of 13.32 million and total assets of 107.52 million.

As of Jun 18, scPharmaceuticals, Inc. has a market capitalization of 210.64 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 41.98 million for the latest four quarters. However, it also experienced a net profit loss of 90.77 million during the same period.<BR><BR>As of Dec 24, the reporting period shows that scPharmaceuticals, Inc. has shareholder's funds amounting to 13.32 million and total assets of 107.52 million.

What does scPharmaceuticals, Inc. do?

scPharmaceuticals, Inc. is a biopharmaceutical company focused on developing products for subcutaneous delivery, with a market cap of approximately $210.64 million and recent net sales of $12 million, but a net loss of $20 million. The company operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap firm.

Overview:<BR>scPharmaceuticals, Inc. is a biopharmaceutical company engaged in developing pharmaceutical products for subcutaneous delivery within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 12 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -20 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 210.64 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.22 <BR>Return on Equity: 1,354.61% <BR>Price to Book: -41.08<BR><BR>Contact Details:<BR>Address: 2400 District Ave Ste 310, BURLINGTON MA: 01803-5239 <BR>Tel: ['1 617 5170730', '1 781 3016706'] <BR>Fax: 1 302 6555049 <BR>Website: http://www.scpharmaceuticals.com/

Should I buy, sell or hold scPharmaceuticals, Inc.?

Who are in the management team of scPharmaceuticals, Inc.?

As of March 2022, the management team of scPharmaceuticals, Inc. includes Independent Chairman Mr. Jack Khattar, President and CEO Mr. John Tucker, and several Independent Directors: Ms. Mette Agger, Ms. Minnie Baylor-Henry, Ms. Sara Bonstein, Dr. Mason Freeman, and Mr. Frederick Hudson. This team provides executive leadership and governance for the company.

As of March 2022, the management team of scPharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Jack Khattar, who serves as the Independent Chairman of the Board.<BR>- Mr. John Tucker, who holds multiple roles as President, Chief Executive Officer, Principal Executive Officer, Principal Financial Officer, and Director.<BR>- Ms. Mette Agger, Independent Director.<BR>- Ms. Minnie Baylor-Henry, Independent Director.<BR>- Ms. Sara Bonstein, Independent Director.<BR>- Dr. Mason Freeman, Independent Director.<BR>- Mr. Frederick Hudson, Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Is scPharmaceuticals, Inc. overvalued or undervalued?

As of May 10, 2023, scPharmaceuticals, Inc. is classified as risky and appears overvalued due to negative valuation ratios, despite a year-to-date return of 58.76% that outperforms the S&P 500's 12.22%.

As of 10 May 2023, the valuation grade for scPharmaceuticals, Inc. has moved from does not qualify to risky, indicating a more cautious outlook. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -43.25, an EV to EBIT of -3.23, and an EV to EBITDA of -3.24. Compared to peers, scPharmaceuticals has a worse EV to EBITDA ratio than Lexicon Pharmaceuticals, Inc. at -2.8670 and Fulcrum Therapeutics, Inc. at -2.2319, both of which also carry a risky valuation grade.<BR><BR>In terms of stock performance, scPharmaceuticals has shown a year-to-date return of 58.76%, significantly outperforming the S&P 500's 12.22% during the same period, though it lags behind in longer-term comparisons. Overall, the combination of negative valuation metrics and the risky classification suggests that scPharmaceuticals is overvalued in the current market context.

Is scPharmaceuticals, Inc. technically bullish or bearish?

As of August 22, 2025, scPharmaceuticals, Inc. shows a bullish technical trend supported by positive indicators, although mixed signals from Dow Theory suggest caution despite recent outperformance against the S&P 500.

As of 22 August 2025, the technical trend for scPharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. The Bollinger Bands show a bullish signal on the monthly timeframe, while the KST is bullish weekly and mildly bullish monthly. However, the Dow Theory presents a mildly bullish weekly and bearish monthly outlook, which adds some caution.<BR><BR>In terms of performance, scPharmaceuticals has outperformed the S&P 500 over the past month with a return of 17.57% compared to the S&P 500's 2.33%, but it has lagged over longer periods, particularly in the 5-year and 10-year comparisons. Overall, the current technical stance is bullish, supported by several key indicators, although the mixed signals from Dow Theory suggest a need for vigilance.